Cachexia is Prevalent in Patients with Hepatocellular Carcinoma and Associated with Worse Prognosis.

[1]  J. Lai,et al.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021, Hepatology.

[2]  A. Montano‐Loza,et al.  Sarcopenia and frailty in decompensated cirrhosis. , 2021, Journal of hepatology.

[3]  William M. Lee,et al.  High Neutrophil–Lymphocyte Ratio and Delta Neutrophil–Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer , 2021, Digestive Diseases and Sciences.

[4]  M. Bouché,et al.  A Pound of Flesh: What Cachexia Is and What It Is Not , 2021, Diagnostics.

[5]  P. Iyengar,et al.  Janus kinase inhibitors suppress cancer cachexia‐associated anorexia and adipose wasting in mice , 2020, JCSM rapid communications.

[6]  Jasmin A. Tiro,et al.  Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma , 2020, Alimentary pharmacology & therapeutics.

[7]  J. Marrero,et al.  Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis , 2020, Gut.

[8]  J. Marrero,et al.  Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis , 2020, Hepatology.

[9]  E. Tapper,et al.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  D. Ganger,et al.  Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. , 2019, Gastroenterology.

[11]  D. Volkert,et al.  Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients , 2019, BMC Geriatrics.

[12]  A. Singal,et al.  Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  M. Plauth,et al.  ESPEN guideline on clinical nutrition in liver disease. , 2019, Clinical nutrition.

[14]  W. Haverkamp,et al.  Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review , 2019, Journal of cachexia, sarcopenia and muscle.

[15]  J. Marrero,et al.  Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  K. Covinsky,et al.  Physical frailty after liver transplantation , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[18]  P. Iyengar,et al.  Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. , 2018, JCI insight.

[19]  P. Iyengar,et al.  Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer. , 2018, Journal of oncology practice.

[20]  P. Iyengar,et al.  Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care. , 2018, Journal of oncology practice.

[21]  C. McCulloch,et al.  The Liver Frailty Index Improves Mortality Prediction of the Subjective Clinician Assessment in Patients With Cirrhosis , 2018, The American Journal of Gastroenterology.

[22]  A. Neugut,et al.  Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[23]  Jennifer C Lai,et al.  Development of a novel frailty index to predict mortality in patients with end‐stage liver disease , 2017, Hepatology.

[24]  H. El‐Serag,et al.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  Shiying Yu,et al.  An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status , 2015, Nutrition and cancer.

[26]  M. Muscaritoli,et al.  Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. , 2015, Critical reviews in oncology/hematology.

[27]  H. Matsubara,et al.  Cancer cachexia, mechanism and treatment. , 2015, World journal of gastrointestinal oncology.

[28]  A. Abernethy,et al.  Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. , 2015, Journal of pain and symptom management.

[29]  J. Ross,et al.  Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[30]  D. Bolignano,et al.  Emerging markers of cachexia predict survival in cancer patients , 2014, BMC Cancer.

[31]  Shuling Chen,et al.  The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis , 2014, Journal of Cancer Research and Clinical Oncology.

[32]  M. Sawyer,et al.  Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma , 2013, Journal of clinical gastroenterology.

[33]  T. Yamanaka,et al.  Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma , 2013, The British journal of surgery.

[34]  A. Asakawa,et al.  Cancer cachexia—pathophysiology and management , 2013, Journal of Gastroenterology.

[35]  Chia-Yang Hsu,et al.  Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system , 2013, Hepatology.

[36]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[37]  M. Tisdale.  Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[38]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[39]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[40]  K. Fearon,et al.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.

[41]  F. López‐Soriano,et al.  Cytokines in the pathogenesis of cancer cachexia , 2003, Current opinion in clinical nutrition and metabolic care.

[42]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.